Company DescriptionEnvisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately-held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of a marketed prostaglandin analogue ...
